Gastric CancerNCT07435025
Surgery for Obstructed Gastric Carcinoma
A study testing palliative gastric resection and palliative bypass in people with Gastric Cancer, run by Zagazig University at 1 site in Egypt.
Trial summary
The goal of this clinical trial is to find the best treatment for obstructed gastric carcinoma in gastric cancer patients. It will include all patients with obstructed gastric cancer with different ages and sex who consented to share in the trial. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Gastric Cancer
- What is being tested?
- palliative gastric resection and palliative bypass
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 63 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Feb 2026to 1 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- emergency obstructed gastric cancer patients
Who cannot join
- non obstructed gastric cancer patients
Trial locations and contacts
1 site in 1 country.
Egypt1 site
faculty of medicine, Zagazig University
Zagazig, Sharqia Province, 44519
About this study
Official title: Palliative Resection Versus Palliative Bypass in Obstructed Locally Advanced Gastric Carcinoma
The goal of this clinical trial is to find the best treatment for obstructed gastric carcinoma in gastric cancer patients. It will include all patients with obstructed gastric cancer with different ages and sex who consented to share in the trial. The main question is what is the better for management for obstructed gastric cancer; palliative resection or palliative bypass? We hypothesized that resection is better. patients will be divided into two groups. the primary outcome measure will be the relief of obstruction
- Conditions
- Gastric Cancer
- Being tested
- palliative gastric resection, palliative bypass
- Keywords
- gastrectomy, palliative, bypass
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
palliative gastric resectionProcedure or surgery
distal, subtotal or total gastrectomy with gastro-jejunostomy or eosphago-jejunostomy will be done
palliative bypassProcedure or surgery
palliative gastro-jejunostomy or eosphago-jejunostomy will be done
| Study group | Role | What they receive |
|---|---|---|
| Group I: obstructed gastric cancer patients | Active comparator | patients presented with emergency gastric obstruction Receives: Procedure: palliative gastric resection |
| Group II: obstructed gastric cancer patients | Active comparator | patients presented with emergency gastric obstruction Receives: Procedure: palliative bypass |
What is being measured
The primary outcome is the main question the study is designed to answer.
upper gastrointestinal symptoms
upper gastrointestinal symptoms will be evaluated after surgery by Rhodes Index questionnaire. It is a validated, self-report instrument used to measure the intensity, frequency, and distress of upper gastrointestinal symptoms. The scale measures three main areas: nausea (frequency, duration, distress), vomiting (amount, frequency, distress), and retching (frequency, distress). It utilizes a 5-point Likert scale (0-4) to quantify the severity of these symptoms. 0 is the least amount of distress and 4 is the most distress.
Measured: from one day to two weeks after surgery
Secondary outcomes (4)
anastmotic leak
anastmotic site leakage will be assessed by abnormal discharge in the drain calculated in cc.
Measured: from day one to two weeks after surgery.
ICU admission
the need of ICU admission will be evaluated by (yes or No)
Measured: from day one to two weeks after surgery
wound infection
wound infection will be identified by presence of pus in the dressing and positive culture and sensitivity test
Measured: from day one to one month after surgery
mortality
follow up of patient after surgery (died or not)
Measured: from one day to one month after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2026
- Study start1 Feb 2026
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 63 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Zagazig University
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Reham Zakaria Mohamed Ahmed, Zagazig University
- Investigators
- Reham Zakaria, M.D, Principal investigator, Zagazig University, Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07435025
- Sponsor's protocol ID
- 2105\17-Feb-2026
- Status last verified
- Feb 2026
- First submitted
- 19 Feb 2026
- Last updated
- 27 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: data will be available on demand by contacting the principle investigator
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Palliative Resection Versus Palliative Bypass in Obstructed Locally Advanced Gastric Carcinoma
- ClinicalTrials.gov ID
- NCT07435025
- Acronym / sponsor ID
- 2105\17-Feb-2026
- Conditions
- Gastric Cancer
- Keywords
- gastrectomy, palliative, bypass
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 63 participants (estimated)
- Lead sponsor
- Zagazig UniversityOther government
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 27 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to find the best treatment for obstructed gastric carcinoma in gastric cancer patients. It will include all patients with obstructed gastric cancer with different ages and sex who consented to share in the trial. The main question is what is the better for management for obstructed gastric cancer; palliative resection or palliative bypass? We hypothesized that resection is better. patients will be divided into two groups. the primary outcome measure will be the relief of obstruction
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I: obstructed gastric cancer patients | Active comparator | Procedure: palliative gastric resectionpatients presented with emergency gastric obstruction |
| Group II: obstructed gastric cancer patients | Active comparator | Procedure: palliative bypasspatients presented with emergency gastric obstruction |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- emergency obstructed gastric cancer patients
Key exclusion criteria (1 listed)
- non obstructed gastric cancer patients
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| palliative gastric resectiondistal, subtotal or total gastrectomy with gastro-jejunostomy or eosphago-jejunostomy will be done | Procedure or surgery | Group I: obstructed gastric cancer patients |
| palliative bypasspalliative gastro-jejunostomy or eosphago-jejunostomy will be done | Procedure or surgery | Group II: obstructed gastric cancer patients |
Primary outcome
upper gastrointestinal symptoms
Time frame: from one day to two weeks after surgery
upper gastrointestinal symptoms will be evaluated after surgery by Rhodes Index questionnaire. It is a validated, self-report instrument used to measure the intensity, frequency, and distress of upper gastrointestinal symptoms. The scale measures three main areas: nausea (frequency, duration, distress), vomiting (amount, frequency, distress), and retching (frequency, distress). It utilizes a 5-point Likert scale (0-4) to quantify the severity of these symptoms. 0 is the least amount of distress and 4 is the most distress.
4 secondary outcomes
anastmotic leak
Time frame: from day one to two weeks after surgery.
ICU admission
Time frame: from day one to two weeks after surgery
wound infection
Time frame: from day one to one month after surgery
mortality
Time frame: from one day to one month after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: Yes. data will be available on demand by contacting the principle investigator
Related trials for Gastric Cancer
RecruitingObservational study
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Colorectal Neoplasms, Gastric Neoplasms
RecruitingPhase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast Neoplasms, Colorectal Neoplasms
Active, not recruitingPhase 2
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Stomach Neoplasms, Immune Checkpoint Inhibitors
Active, not recruitingPhase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Advanced Solid Tumor, Metastatic Solid Tumor
RecruitingPhase 1/2
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Reham Zakaria, M.D principal investigator
Zagazig University, Egypt
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing palliative gastric resection and palliative bypass in people with Gastric Cancer, run by Zagazig University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
upper gastrointestinal symptoms (time frame: from one day to two weeks after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.